Sheri L. Holmen

Professor

University of Utah Health Sciences Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes preclinical and clinical evidence on the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, emphasizing mechanisms of blood–brain barrier traversal, tumor-stroma co-option, and brain-specific genomic and transcriptional programs. We summarize advances in therapeutic strategies to combat melanoma brain metastasis including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.

Year:

2026

Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes recent advances in understanding the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, with a specific emphasis on brain metastasis. We explore the unique challenges of brain metastasis, including blood-brain barrier penetration, brain-specific microenvironment interactions, and genomic distinctions. Advances in diagnostic tools, such as imaging and liquid biopsies, are discussed alongside current and emerging therapeutic strategies, including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.

Year:

2026

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.

Year:

2024

Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo . Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.

Year:

2024

Supplementary Figure S7 shows chemical structures of all pharmacological agents utilized in study, including MK2206, GSK2141795, GDC-0941, BYL719, RapaLink-1, GSK650394, GDC-0068, GDC-0084, and INY-03-041.

Year:

2024

Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P

Year:

2024

Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P

Year:

2024

Supplementary Figure S4 demonstrates that siAKT1-3 is specific for human AKT. A, The cell confluency assay of YUMM1.1 mouse melanoma cells under genetic inhibition demonstrated no effect on cell death with siAKT1, siAKT2, siAKT3, or any combination. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of YUMM1.1 cells treated with siCtrl vs siAKT1-3. No knockdown of P-AKT (Ser473) or P-PRAS40 (T246) indicated the specificity of the siRNAs for human AKT.

Year:

2024

Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo . Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (27)

Yuting Lu

New York University

UNITED STATES
View details

Graham Mann

Professor

University of Sydney

AUSTRALIA
View details

Adam Reynolds

Research Assistant Professor

University of New Mexico

UNITED STATES
View details

Shaofeng Yan

-

UNITED STATES
View details

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Cheryl Thompson

Professor and Associate Director for Population Sciences, Penn State Cancer Institute

Pennsylvania State University

UNITED STATES
View details

Christopher I. Amos

Associate Director for Population and Data Science

Baylor College of Medicine

UNITED STATES
View details

Pauline Funchain

Stanford University

UNITED STATES
View details

Marcus Bosenberg

Professor

Yale University

UNITED STATES
View details

Riley Elmer

University of Southern California

UNITED STATES
View details

Marianne Berwick

Professor

University of New Mexico

UNITED STATES
View details

David Ollila

Professor of Surgery

University of North Carolina at Chapel Hill

UNITED STATES
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

Anne E Cust

Deputy Director, The Daffodil Centre

University of Sydney

AUSTRALIA
View details

David Polsky

Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)

NYU School of Medicine

UNITED STATES
View details

Tim Lee

The University of British Columbia

UNITED STATES
View details

Pei-Fen Kuan

Professor

Stony Brook University

UNITED STATES
View details

Paul Googe

Professor and Laboratory Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

Robert Judson‐Torres

-

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Iman Osman

NYU Langone Health

UNITED STATES
View details

Eva Hernando

Professor

NYU Langone Medical Center

UNITED STATES
View details

Gennie Parkman

Assistant Professor

Weber State University

UNITED STATES
View details

Martin McMahon

Cumming-Presidential Chair of Cancer Biology

University of Utah

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

Kayla O'Toole

University of Utah

UNITED STATES
View details

E. Nagore

Profesor Asociado

Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología

SPAIN
View details